Clinical Trials Logo
  1. Home
  2. Carcinoma, Non-Small-Cell Lung
  3. NCT05937074
  4. Details
NCT05937074 Clinical Trial

Metabolic Response to Food in Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

— METRIC  

Official title:
Metabolic Response to Food in Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05937074
Other study ID # PBRC 2023-017
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 18, 2023
Est. completion date June 30, 2025

Study information
Verified date April 2024
Source Pennington Biomedical Research Center
Contact Stephanie Compton, Ph.D.
Phone 225-763-2715
Email Stephanie.Compton@pbrc.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This goal of this study is to describe how unintentional weight loss influences fasting and post-prandial metabolic flexibility in participants with advanced non-small cell lung cancer.

Recruitment information / eligibility
Status Recruiting
Enrollment 12
Est. completion date June 30, 2025
Est. primary completion date June 30, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age greater than or equal to 18 years - Diagnosis of non-small-cell lung cancer - Reported weight stability or loss after cancer diagnosis - Body mass index less than or equal to 35 kilograms per meter squared - Ability to provide written informed consent - Willing and able to comply with all scheduled visits, treatment plans, lab tests, and other study procedure - Allow the collection and storage of biospecimens and data for future use Exclusion Criteria: - Prior diagnosis of diabetes mellitus (type 1 or type 2) - Currently pregnant or breastfeeding - Contraindication to consuming the liquid mixed meal - Any medications affecting gastric motility - Any other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Weight loss (%)
Change in body weight from cancer diagnosis to study enrollment

Locations
Country Name City State
United States Pennington Biomedical Research Center Baton Rouge Louisiana

Sponsors (1)
Lead Sponsor Collaborator
Pennington Biomedical Research Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Respiratory quotient The respiratory quotient will be measured by indirect calorimetry before and after consumption of a liquid mixed meal Difference between pre- to post-prandial conditions over four hours
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Completed NCT04426825 - A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Phase 2
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) Phase 3
Completed NCT02810457 - Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer Phase 3
Recruiting NCT04592523 - A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Recruiting NCT04838548 - A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04077463 - A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer Phase 1
Recruiting NCT04603807 - A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Phase 3
Recruiting NCT05167604 - Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
Completed NCT04948411 - Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Active, not recruiting NCT04487080 - A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase 3
Not yet recruiting NCT04255836 - Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01953913 - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Phase 3
Recruiting NCT05715229 - Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy Phase 2
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Suspended NCT05421936 - Osimertinib for NSCLC With Uncommon EGFR Mutations
Completed NCT02847377 - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC N/A
Completed NCT04427072 - Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Phase 3
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A